Valeant Pharmaceuticals International - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 136

Valeant Pharmaceuticals International – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Valeant Pharmaceuticals International - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Valeant Pharmaceuticals International - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Valeant Pharmaceuticals International human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Valeant Pharmaceuticals International with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Valeant Pharmaceuticals International’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Valeant Pharmaceuticals International’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Valeant Pharmaceuticals International in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Valeant Pharmaceuticals International’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Valeant Pharmaceuticals International.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Valeant Pharmaceuticals International and identify potential opportunities in those areas.

List of Tables
List of Figures
Valeant Pharmaceuticals International Snapshot
Valeant Pharmaceuticals International Overview
Key Information
Key Facts
Valeant Pharmaceuticals International – Research and Development Overview
Key Therapeutic Areas
Valeant Pharmaceuticals International – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Valeant Pharmaceuticals International – Pipeline Products Glance
Valeant Pharmaceuticals International – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Valeant Pharmaceuticals International Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Valeant Pharmaceuticals International–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Valeant Pharmaceuticals International – Drug Profiles
Potiga
Product Description
Mechanism of Action
R&D Progress
Retigabine
Product Description
Mechanism of Action
R&D Progress
Cesamet
Product Description
Mechanism of Action
R&D Progress
IDP 108
Product Description
Mechanism of Action
R&D Progress
IDP 115
Product Description
Mechanism of Action
R&D Progress
KP-103
Product Description
Mechanism of Action
R&D Progress
IDP-107
Product Description
Mechanism of Action
R&D Progress
Potiga
Product Description
Mechanism of Action
R&D Progress
Retigabine
Product Description
Mechanism of Action
R&D Progress
Taribavirin
Product Description
Mechanism of Action
R&D Progress
VRX806
Product Description
Mechanism of Action
R&D Progress
BVF-018
Product Description
Mechanism of Action
R&D Progress
IDP 113
Product Description
Mechanism of Action
R&D Progress
Potiga
Product Description
Mechanism of Action
R&D Progress
BVF-014
Product Description
Mechanism of Action
R&D Progress
Valeant Pharmaceuticals International – Pipeline Analysis
Valeant Pharmaceuticals International – Pipeline Products by Therapeutic Class
Valeant Pharmaceuticals International Pipeline Products By Target
Valeant Pharmaceuticals International – Pipeline Products by Route of Administration
Valeant Pharmaceuticals International – Pipeline Products by Molecule Type
Valeant Pharmaceuticals International – Recent Pipeline Updates
Valeant Pharmaceuticals International - Dormant Projects
Valeant Pharmaceuticals International - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BVF-045
BVF-324
RUS-350
Valeant Pharmaceuticals International – Company Statement
Valeant Pharmaceuticals International – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Valeant Pharmaceuticals International - Key Manufacturing Facilities
Recent Developments
Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine
Aug 30, 2010: GSK And Valeant Receive New FDA PDUFA Goal Date For Ezogabine
Aug 11, 2010: GSK And Valeant Receive Positive Vote From FDA Advisory Committee For Ezogabine For Treatment Of Epilepsy
Jun 23, 2010: Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra
Jun 23, 2010: Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra
Jun 23, 2010: Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra
Jun 23, 2010: Valeant Pharmaceuticals Resumes Shipment Of Oxsoralen-Ultra
May 10, 2010: Valeant Receives Regulatory Approval For Onsolis In Canada
May 03, 2010: Aton Pharma, Inc. Acquisition
May 03, 2010: Aton Pharma, Inc. Acquisition
Financial Deals Landscape
Valeant Pharmaceuticals International, Deals Volume Summary, 2004 to YTD 2010
Valeant Pharmaceuticals International, Deals Summary By Region, 2004 to YTD 2010
Valeant Pharmaceuticals International, Deals Summary, 2004 to YTD 2010
Valeant Pharmaceuticals International Detailed Deal Summary
Asset Purchase
Valeant Pharmaceuticals Acquires Polish Dermatological Products
Acquisition
Valeant Pharmaceuticals Acquires Private Formula International Holdings
Valeant Pharmaceuticals Completes Acquisition Of Tecnofarma
Valeant Acquires EMO-FARM
Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences
Valeant Pharmaceuticals Acquires DermaTech
Valeant Pharmaceuticals Acquires Coria Laboratories From DFB Pharmaceuticals
Valeant Pharmaceuticals Acquires Xcel Pharmaceuticals
Valeant Pharmaceuticals Acquires Amarin Pharmaceuticals
ICN Pharmaceuticals Acquires CoolTouch
Equity Offering
Valeant Pharmaceuticals Completes Public Offering Of $199 Million
Debt Offering
Valeant Pharmaceuticals Completes Placement Of 8.375% Senior Notes For $365 Million
Valeant Pharmaceuticals Enters Into Agreement With GlaxoSmithKline
Valeant Pharmaceuticals Enters Into Joint Venture With Meda
Valeant Pharmaceuticals Enters Into Co-Promotion Agreement With Ascend Therapeutics
JSJ Pharmaceuticals Enters Into Co-Marketing Agreement With Valeant Pharmaceuticals
Valeant Pharmaceuticals Terminates Co-Promotion Agreement With Par Pharmaceutical
Valeant Pharmaceuticals Enters Into Co-Marketing Agreement With Intendis
Par Pharmaceutical Enters Into Co-Promotion Agreement With Valeant Pharmaceuticals
Valeant Pharmaceuticals Enters Into Co-Marketing Agreement With Allergan
Alliance Pharma Enters Into Co-Promotion Agreement With Valeant Pharmaceuticals
Valeant Pharmaceuticals Enters Into Co-Promotion Agreement With Caleel + Hayden
Licensing Agreements
Penwest And Endo Pharmaceuticals Enters Into Licensing Agreement With Valeant
GlaxoSmithKline Enters Into Licensing Agreement With Valeant Pharmaceuticals
Valeant Pharmaceuticals Enters into Licensing Agreement With Jazz Pharmaceuticals
Schering-Plough Signs Licensing Agreement With Valeant Pharmaceuticals And Metabasis Therapeutics For Pradefovir
Lescarden Enters Into Licensing Agreement With Valeant Pharmaceuticals
Senetek Amends Licensing Agreement With Valeant Pharmaceuticals
Lescarden Terminates Licensing Agreement With Valeant Pharmaceuticals
Valeant Pharmaceuticals Enters Into Option Licening Agreement With Schering-Plough
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Aerospace and Defence Industry - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• Electronic Warfare Systems - Global Strategic Business Report